Paragon Capital Management LLC Boosts Stock Holdings in CVS Health Corp (NYSE:CVS)

Paragon Capital Management LLC raised its holdings in shares of CVS Health Corp (NYSE:CVS) by 4.5% during the second quarter, according to its most recent filing with the SEC. The firm owned 94,837 shares of the pharmacy operator’s stock after purchasing an additional 4,055 shares during the period. CVS Health accounts for about 2.3% of Paragon Capital Management LLC’s portfolio, making the stock its 18th largest position. Paragon Capital Management LLC’s holdings in CVS Health were worth $5,168,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CVS. FMR LLC boosted its stake in CVS Health by 30.6% in the 4th quarter. FMR LLC now owns 39,263,265 shares of the pharmacy operator’s stock worth $2,572,528,000 after purchasing an additional 9,194,005 shares in the last quarter. Geode Capital Management LLC boosted its stake in CVS Health by 36.2% in the 4th quarter. Geode Capital Management LLC now owns 16,462,292 shares of the pharmacy operator’s stock worth $1,076,697,000 after purchasing an additional 4,376,604 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in CVS Health by 28.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 13,790,753 shares of the pharmacy operator’s stock worth $903,574,000 after purchasing an additional 3,041,266 shares in the last quarter. Norges Bank acquired a new stake in CVS Health in the 4th quarter worth approximately $840,254,000. Finally, Nordea Investment Management AB boosted its stake in CVS Health by 2.8% in the 1st quarter. Nordea Investment Management AB now owns 12,426,745 shares of the pharmacy operator’s stock worth $670,172,000 after purchasing an additional 340,315 shares in the last quarter. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of NYSE:CVS traded down $1.02 during trading on Friday, hitting $61.03. 2,054,460 shares of the stock traded hands, compared to its average volume of 9,224,633. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.39. The company has a market cap of $80.06 billion, a price-to-earnings ratio of 8.62, a P/E/G ratio of 1.35 and a beta of 0.90. The company has a fifty day moving average price of $57.21 and a two-hundred day moving average price of $56.35. CVS Health Corp has a 52-week low of $51.72 and a 52-week high of $82.15.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.19. The firm had revenue of $63.43 billion during the quarter, compared to analyst estimates of $62.66 billion. CVS Health had a net margin of 1.91% and a return on equity of 16.15%. The business’s quarterly revenue was up 35.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.69 EPS. On average, equities research analysts predict that CVS Health Corp will post 6.96 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, August 2nd. Stockholders of record on Thursday, July 25th were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 3.28%. The ex-dividend date of this dividend was Wednesday, July 24th. CVS Health’s dividend payout ratio (DPR) is 28.25%.

Several analysts have commented on the stock. Morgan Stanley restated a “buy” rating and set a $74.00 price objective on shares of CVS Health in a research note on Sunday, August 11th. Credit Suisse Group cut shares of CVS Health from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $73.00 to $61.00 in a research note on Monday, April 29th. Cantor Fitzgerald restated a “buy” rating and set a $80.00 price objective on shares of CVS Health in a research note on Wednesday, May 1st. Standpoint Research upgraded shares of CVS Health from a “hold” rating to a “buy” rating in a research note on Wednesday, June 5th. Finally, Mizuho set a $71.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research note on Wednesday, June 5th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. CVS Health presently has an average rating of “Buy” and a consensus target price of $75.14.

About CVS Health

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Story: If I purchase shares through a brokerage account, am I the holder of record?

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.